PD-L1 and tumor-associated macrophages in de novo DLBCL

per McCord, Ronald, Bolen, Christopher R., Koeppen, Hartmut, Kadel, Edward E., Oestergaard, Mikkel Z., Nielsen, Tina, Sehn, Laurie H., Venstrom, Jeffrey M.
Publicat a Blood Adv (2019)

In silico tools for accurate HLA and KIR inference from clinical sequencing data empower immunogenetics on individual-patient and population scales

per Chen, Jieming, Madireddi, Shravan, Nagarkar, Deepti, Migdal, Maciej, Vander Heiden, Jason, Chang, Diana, Mukhyala, Kiran, Selvaraj, Suresh, Kadel, Edward E, Brauer, Matthew J, Mariathasan, Sanjeev, Hunkapiller, Julie, Jhunjhunwala, Suchit, Albert, Matthew L, Hammer, Christian
Publicat a Brief Bioinform (2020)

Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC)

per Powles, Thomas, Nickles, Dorothee, Van Allen, Eliezer, Chappey, Colombe, Zou, Wei, Kowanetz, Marcin, Kadel, Edward, Denker, Mitchell, Boyd, Zachary, Vogelzang, Nicholas, Kim, Joseph, Bellmunt, Joaquim, Loriot, Yohann, Drake, Charles G, O'Hear, Carol, Fasso, Marcella, Hegde, Priti, Mariathasan, Sanjeev
Publicat a J Immunother Cancer (2015)

The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells

per Luqman, Mohammad, Klabunde, Sha, Lin, Karen, Georgakis, Georgios V., Cherukuri, Anu, Holash, Jocelyn, Goldbeck, Cheryl, Xu, Xiaomei, Kadel, Edward E., Lee, Sang Hoon, Aukerman, Sharon Lea, Jallal, Bahija, Aziz, Natasha, Weng, Wen-Kai, Wierda, William, O'Brien, Susan, Younes, Anas
Publicat 2008

Molecular determinants of response to PD-L1 blockade across tumor types

per Banchereau, Romain, Leng, Ning, Zill, Oliver, Sokol, Ethan, Liu, Gengbo, Pavlick, Dean, Maund, Sophia, Liu, Li-Fen, Kadel, Edward, Baldwin, Nicole, Jhunjhunwala, Suchit, Nickles, Dorothee, Assaf, Zoe June, Bower, Daniel, Patil, Namrata, McCleland, Mark, Shames, David, Molinero, Luciana, Huseni, Mahrukh, Sanjabi, Shomyseh, Cummings, Craig, Mellman, Ira, Mariathasan, Sanjeev, Hegde, Priti, Powles, Thomas
Publicat a Nat Commun (2021)

High systemic and tumor-associated IL8 correlates with reduced clinical benefit of PD-L1 blockade

per Yuen, Kobe C., Liu, Lifen, Gupta, Vinita, Madireddi, Shravan, Keerthivasan, Shilpa, Li, Congfen, Rishipathak, Deepali, Williams, Patrick, Kadel, Edward E., Koeppen, Hartmut, Chen, Ying-Jiun, Modrusan, Zora, Grogan, Jane L., Banchereau, Romain, Leng, Ning, Thastrom, AnnChristine, Shen, Xiadong, Hashimoto, Kenji, Tayama, Darren, van der Heijden, Michiel S., Rosenberg, Jonathan E., McDermott, David F., Powles, Thomas, Hegde, Priti S., Huseni, Mahrukh A., Mariathasan, Sanjeev
Publicat a Nat Med (2020)

Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)

per Kowanetz, Marcin, Zou, Wei, Gettinger, Scott N., Koeppen, Hartmut, Kockx, Mark, Schmid, Peter, Kadel, Edward E., Wistuba, Ignacio, Chaft, Jamie, Rizvi, Naiyer A., Spigel, David R., Spira, Alexander, Hirsch, Fred R., Cohen, Victor, Smith, Dustin, Boyd, Zach, Miley, Natasha, Flynn, Susan, Leveque, Vincent, Shames, David S., Ballinger, Marcus, Mocci, Simonetta, Shankar, Geetha, Funke, Roel, Hampton, Garret, Sandler, Alan, Amler, Lukas, Mellman, Ira, Chen, Daniel S., Hegde, Priti S.
Publicat a Proc Natl Acad Sci U S A (2018)

Atezolizumab as first-line therapy in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

per Balar, Arjun V, Galsky, Matthew D, Rosenberg, Jonathan E, Powles, Thomas, Petrylak, Daniel P, Bellmunt, Joaquim, Loriot, Yohann, Necchi, Andrea, Hoffman-Censits, Jean, Perez-Gracia, Jose Luis, Dawson, Nancy A, van der Heijden, Michiel S, Dreicer, Robert, Srinivas, Sandy, Retz, Margitta M, Joseph, Richard W, Drakaki, Alexandra, Vaishampayan, Ulka N, Sridhar, Srikala S, Quinn, David I, Durán, Ignacio, Shaffer, David R, Eigl, Bernhard J, Grivas, Petros D, Yu, Evan Y, Li, Shi, Kadel, Edward E, Boyd, Zachary, Bourgon, Richard, Hegde, Priti S, Mariathasan, Sanjeev, Thåström, AnnChristine, Abidoye, Oyewale O, Fine, Gregg D, Bajorin, Dean F
Publicat a Lancet (2016)

TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

per Mariathasan, Sanjeev, Turley, Shannon J., Nickles, Dorothee, Castiglioni, Alessandra, Yuen, Kobe, Wang, Yulei, Kadel, Edward E., Koeppen, Hartmut, Astarita, Jillian L., Cubas, Rafael, Jhunjhunwala, Suchit, Banchereau, Romain, Yang, Yagai, Guan, Yinghui, Chalouni, Cecile, Ziai, James, Şenbabaoğlu, Yasin, Santoro, Stephen, Sheinson, Daniel, Hung, Jeffrey, Giltnane, Jennifer M., Pierce, Andrew K., Mesh, Kathryn, Lianoglou, Steve, Riegler, Johannes, Carano, Richard A. D., Eriksson, Pontus, Hoglund, Mattias, Somarriba, Loan, Halligan, Daniel L., van der Heijden, Michiel, Loriot, Yohann, Rosenberg, Jonathan E., Fong, Lawrence, Mellman, Ira, Chen, Daniel S., Green, Marjorie, Derleth, Christina, Fine, Gregg D., Hegde, Priti S., Bourgon, Richard, Powles, Thomas
Publicat a Nature (2018)